Ocrelizumab designated a ‘Breakthrough Therapy’ by FDA for primary progressive MS

Genentech, a member of the Roche Group, announced in a February 16 press release that the experimental therapy ocrelizumab has been granted ‘Breakthrough Therapy designation’ by the US Food and Drug Administration (FDA) for the treatment of people with primary progressive MS. To read more, click on the link below:

Ocrelizumab designated a ‘Breakthrough Therapy’ by FDA for primary progressive MS

Article courtesy of MS Research Australia www.msra.org.au